UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
Amendment No. 1
(Mark One)
☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended: December 31, 2018
Or
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number:001-38130
Aileron Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 13-4196017 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
490 Arsenal Way, Suite 210
Watertown, MA 02472
(Address of Principal Executive Offices) (zip code)
Registrant’s telephone number, including areacode: (617) 995-0900
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of RegulationS-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 ofRegulation S-K (§229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of thisForm 10-K or any amendment to thisForm 10-K. ☒
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant is a shell company (as defined inRule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of June 29, 2018, the last day of the Registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting andnon-voting common equity held bynon-affiliates of the Registrant, based on the last reported sale price of the shares of common stock on The Nasdaq Global Market was $40,753,229.
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Common Stock, $0.001 par value | ALRN | The Nasdaq Global Market |
Securities registered pursuant to Section 12(g) of the Act:
None
As of March 26, 2019, the Registrant has 14,875,035 shares of Common Stock, $0.001 par value per share, outstanding.
Documents incorporated by reference:
Portions of the Registrant’s definitive proxy statement for its 2019 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form10-K.
EXPLANATORY NOTE
Aileron Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 onForm 10-K/A (“Amendment”) to its Annual Report on Form10-K for the fiscal year ended December 31, 2018, as originally filed with the Securities and Exchange Commission on March 29, 2019 (the “Original Filing”), solely to replace Exhibit 23.1Consent of Independent Registered Public Accounting Firm included in the Original Filing with a corrected Exhibit 23.1. The Exhibit 23.1 included in the Original Filing inadvertently omitted the Registration Statement onForm S-8(No. 333-224785) from the list of registration statements as to which consent was provided by PricewaterhouseCoopers LLP. The Exhibit 23.1 included in the Original Filing also identified the report date as March 28, 2019 whereas the appropriate date is March 29, 2019. A new Exhibit 23.1 with the appropriate corrections is filed as Exhibit 23.1 attached hereto.
This Amendment speaks as of the original filing date and does not reflect events occurring after the filing of the Form10-K or modify or update disclosures that may be affected by subsequent events. No revisions are being made to the Company’s financial statements or any other disclosure contained in the Form10-K. This Amendment is an exhibit-only filing. Except for Exhibit 23.1, this Amendment does not otherwise update any exhibits as originally filed or previously amended.
In addition, as required by Rule12b-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment pursuant to Rule13a-14(a) or15d-14(a) of the Exchange Act. As no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of RegulationS-K, paragraphs 3, 4, and 5 of the certifications have been omitted. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) as no financial statements are being filed with this Amendment.
PART IV
ITEM 15. | Exhibits, Financial Statement Schedules |
(c) Exhibits.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Aileron Therapeutics, Inc. | ||||||
Date: May 8, 2019 | By: | /s/ Manuel C. Alves Aivado, M.D., Ph.D. | ||||
Manuel C. Alves Aivado, M.D., Ph.D. | ||||||
President and Chief Executive Officer | ||||||
(principal executive officer) |